,
1 min read
Market Context
Australia remains a high-value, tightly regulated pharmaceutical market. However, with increasing scrutiny from the Therapeutic Goods Administration (TGA), sponsors are experiencing longer review timelines and more detailed evaluations.
Gaining entry into the Australian Register of Therapeutic Goods (ARTG) is no longer just procedural—it’s strategic.
Regulatory Explanation
ARTG inclusion is mandatory for supplying therapeutic products in Australia.
It requires:
- CTD/eCTD-compliant dossiers
- Region-specific Module 1 documentation
- GMP clearance for manufacturing sites
- Strong quality, safety, and efficacy data
Even well-prepared global dossiers require Australia-specific adaptation.
Problem
Sponsors commonly face:
- Delays due to incomplete Module 1 localization
- GMP clearance bottlenecks for overseas facilities
- Multiple rounds of TGA queries
- Misalignment between global and local regulatory expectations
- Lack of structured lifecycle management post-approval
These gaps can significantly extend timelines and increase compliance risk.
Freyr Solutions
Freyr supports sponsors with a precision-driven regulatory approach:
- Regulatory gap assessment & submission readiness strategy
- TGA-compliant Module 1 preparation
- End-to-end CTD/eCTD compilation & publishing
- GMP clearance coordination & authority liaison
- Structured query handling to reduce review cycles
- Lifecycle management (LCM) for post-approval compliance
Outcome: Faster approvals, fewer queries, and sustained compliance.
Global Angle
For global manufacturers, the real challenge is balancing global consistency with local compliance.
Freyr bridges this gap by integrating:
- Global regulatory strategy
- Local TGA expertise
- Streamlined documentation processes
This ensures efficiency without duplication across markets.
In Australia, regulatory success isn’t just about getting listed—it’s about getting listed right and staying compliant.
Is your ARTG strategy built for approval—or for long-term market continuity?
If Australia is part of your 2026 roadmap, now is the time to assess your submission readiness.
Connect with Freyr to streamline your ARTG pathway and reduce regulatory risk.
